Research Article
Robust Optimization of Alginate-Carbopol 940 Bead Formulations
Table 1
Some of the factors affecting the encapsulation process of drugs into alginate beads.
| Factor | | Drug | Effect | Reference |
| Related with the formulation | | | Gliclazide | | | Alginate concentration | | | + EE | | | | + diameter | | | | −porosity |
[7] | | | −release rate | | | | + swelling | | | BSA | + EE | [5, 8] | | Glucose | | |
| Volume of the alginate solution | | Gliclazide | −diameter | [7] |
| Divalent cation concentration | | BSA | −EE | [5, 8, 9] | | VEGF | | Glucose |
| Crosslinker/alginate ratio | Neutral (xanthan gums, ethylcellulose, PVA) | Diclofenac sodium | + EE | [10, 11] | + swelling | Cationic (chitosan, poli-L-lysine) | Proteins Oligonucleotides | + EE | [3, 5, 12] | Waxy compounds (Compritol 888 ATO, Precirol ATO 5, Gelucires, glyceryl palmitostearate, magnesium aluminum silicate) | Tamsulosin, diclofenac sodium | + EE −release rate | [13–16] |
Anionic (CMC, Eudragit L100, dextran sulphate) and cationic | Insulin | +EE | + diameter | −release rate |
| Surfactant presence | | Gliclazide | −diameter |
[7] | | | | + EE | |
| Related with the process | Needle size | | BSA | −diameter | [5] | Coaxial air volume | | BSA | −diameter | [5] | Drying process | | BSA | | [5] |
| Stirring rate | | Gliclazide | −EE |
[7] | −diameter | |
|
|